Literature DB >> 25696441

Evaluation of cardiac emboli source.

M Michels, F J Meijboom, F J Ten Cate.   

Abstract

BACKGROUND: Evaluating the source of cardiac embolism is one of the most frequent reasons for cardiac consultation.
METHODS: In 2003, 99 patients were referred for the evaluation of the source of cardiac emboli. Evaluation included history, physical examination, ECG, transoesophageal echocardiography (TOE) with contrast and 24-hour Holter electrocardiography.
RESULTS: Altogether, 58 men and 41 women were studied. In 32 patients a possible source of the cardiac emboli was found. Two patients were in atrial fibrillation. Of the patients, 16 had a patent foramen ovale (PFO) and six patients a PFO and atrial septum aneurysm (ASA). Two patients had a thrombus in the left atrial appendage and 14 had severe atherosclerosis in the aortic arch. In eight patients we found two possible cardiac sources of embolism. 24-hour Holter recording did not detect any emboligenic arrhythmias.
CONCLUSION: A possible cardiac source of embolism was found in 32% of the patients referred. TOE is the ideal tool to visualise the interatrial septum, left atrial appendage and aortic arch. We advise performing a TOE with contrast in young stroke patients and in older patients with a stroke likely to be caused by an embolism of cardiac origin. 24-hour Holter recording did not detect any emboligenic arrhythmias and should only be done in selected cases.

Entities:  

Keywords:  cerebrovascular accident; echocardiography; embolism; transoesophageal

Year:  2005        PMID: 25696441      PMCID: PMC2497371     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  11 in total

1.  Transmitral Doppler: a new transthoracic contrast method for patent foramen ovale detection and quantification.

Authors:  A J Kerr; T Buck; K Chia; C M Chow; E Fox; R A Levine; M H Picard
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

2.  Prevalence of patent foramen ovale in patients with stroke.

Authors:  P Lechat; J L Mas; G Lascault; P Loron; M Theard; M Klimczac; G Drobinski; D Thomas; Y Grosgogeat
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

3.  Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.

Authors:  J L Mas; C Arquizan; C Lamy; M Zuber; L Cabanes; G Derumeaux; J Coste
Journal:  N Engl J Med       Date:  2001-12-13       Impact factor: 91.245

4.  Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts.

Authors:  P T Hagen; D G Scholz; W D Edwards
Journal:  Mayo Clin Proc       Date:  1984-01       Impact factor: 7.616

5.  Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: a cost-effectiveness analysis.

Authors:  R L McNamara; J A Lima; P K Whelton; N R Powe
Journal:  Ann Intern Med       Date:  1997-11-01       Impact factor: 25.391

Review 6.  Atrial fibrillation: strategies to control, combat, and cure.

Authors:  Nicholas S Peters; Richard J Schilling; Prapa Kanagaratnam; Vias Markides
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

Review 7.  Cardioembolic stroke: an update.

Authors:  José M Ferro
Journal:  Lancet Neurol       Date:  2003-03       Impact factor: 44.182

8.  Comparison of diagnostic techniques for the detection of a patent foramen ovale in stroke patients.

Authors:  M Di Tullio; R L Sacco; N Venketasubramanian; D Sherman; J P Mohr; S Homma
Journal:  Stroke       Date:  1993-07       Impact factor: 7.914

9.  Value of cardiac monitoring and echocardiography in TIA and stroke patients.

Authors:  J A Rem; V C Hachinski; D R Boughner; H J Barnett
Journal:  Stroke       Date:  1985 Nov-Dec       Impact factor: 7.914

10.  Atrial septal aneurysm and stroke: a transesophageal echocardiographic study.

Authors:  A C Pearson; D Nagelhout; R Castello; C R Gomez; A J Labovitz
Journal:  J Am Coll Cardiol       Date:  1991-11-01       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.